Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

HeartSciences Inc. HSCSW NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Devices • US • USD

SharesGrow Score
28/100
1/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

HeartSciences Inc. (HSCSW) is a Medical - Devices company in the Healthcare sector, currently trading at $0.11. It has a SharesGrow Score of 27/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Valuation: HSCSW trades at a trailing Price-to-Earnings (P/E) of -0.8 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.07.

Financials: revenue is $4,350, +40.1%/yr average growth. Net income is $9M (loss), growing at -3518.6%/yr. Net profit margin is -201499.5% (negative). Gross margin is -2884.7% (-2929.8 pp trend).

Balance sheet: total debt is $3M against $205,171 equity (Debt-to-Equity (D/E) ratio 14.55, leveraged). Current ratio is 0.59 (tight liquidity). Debt-to-assets is 70.7%. Total assets: $4M.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 0/100 (Fail), Moat 0/100 (Fail), Future ?/100 (Fail), Income 10/100 (Fail).

HSCSW SharesGrow Score Overview

56/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 0/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 0/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — HSCSW

✓
VALUE Pass
100/100
HSCSW trades at a trailing Price-to-Earnings (P/E) of -0.8 (S&P 500 average ~25). Forward PEG 0.07 — Peter Lynch undervalued (≤1.0). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
HSCSW: +40.1%/yr revenue is, -3518.6%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
—
HEALTH N/A
N/A
No analyst coverage available for this stock.
—
MOAT N/A
N/A
No analyst coverage available for this stock.
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
HSCSW: Net profit margin is -201499.5%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.0717-0.1174
Volume1
Avg Volume (30D)3.57K
Market Cap$298.13K
Beta (1Y)2.45
Share Statistics
EPS (TTM)-9.34
Shares Outstanding$938.26K
IPO Date2022-06-15
Employees15
CEOAndrew Simpson
Financial Highlights & Ratios
Revenue (TTM)$4.35K
Gross Profit$-125.49K
EBITDA$-8.14M
Net Income$-8.77M
Operating Income$-8.35M
Total Cash$1.1M
Total Debt$2.99M
Net Debt$1.89M
Total Assets$4.22M
Price / Earnings (P/E)-0
Price / Sales (P/S)68.54
Analyst Forecast
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS42254E1120

Price Chart

Track all markets on TradingView
HSCSW
HeartSciences Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Medical - Devices
0.07 52WK RANGE 0.12

People Also View

HSCS
HSCS
Heart Test Laboratories, Inc.
$1.98
+0.51%
 IINNW
IINNW
Inspira Technologies Oxy B.H.N. Ltd.
$0.09
+22.08%
 GMVDW
GMVDW
G Medical Innovations Holdings Ltd
$7.04
-1.13%
 BIAFW
BIAFW
bioAffinity Technologies, Inc.
$0.28
-22.22%
 TCBPW
TCBPW
TC Biopharm (Holdings) Plc
$0.01
+0.00%
 LLY
LLY
Eli Lilly and Company
$905.13
-1.88%
 JNJ
JNJ
Johnson & Johnson
$238.67
-0.60%
 ABBV
ABBV
AbbVie Inc.
$208.43
-0.87%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message